期刊
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 70, 期 11, 页码 2945-2955出版社
OXFORD UNIV PRESS
DOI: 10.1093/jac/dkv192
关键词
-
资金
- TERFIQEC Project: COMPREHENSIVE RESEARCH ON EFFECTIVE THERAPIES FOR THE TREATMENT OF CYSTIC FIBROSIS AND ASSOCIATED DISEASES [IPT-2011-1402-900000]
- Ministry of Economy and Competitiveness
- University of the Basque Country (UPV/EHU), ZabaldUz grant [UFI11/32]
- Basque Government [IT 428-10]
- Consolidated Group of the Basque Government
As the WHO stated, lower respiratory infections are the third leading cause of death. In addition, it is remarkable that antimicrobial resistance represents a huge threat. Thus, new therapeutic weapons are required. Among the possible alternatives, antibiotic encapsulation in nanoparticles has gained much attention in terms of improved tolerability, activity and ability to combat the resistance mechanisms of bacteria. In this regard, this review article focuses on the latest nanocarrier approaches for inhalatory therapy of antibiotics. First, the technology related to lung disposition will be reviewed. Then, nanocarrier systems will be introduced and the challenges required to perform adequate pulmonary deposition analysed. In the following part, drug delivery systems (DDSs) on the market or in clinical trials are described and, finally, new approaches of nanoparticles that have reached preclinical stage are enumerated. Altogether, this review aims at gathering together the novel nanosystems for anti-infectious therapy, underlining the potential of DDSs to improve and optimize currently available antibiotic therapies in the context of lung infections.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据